Preventing miscarriage through platform testing of multiple novel interventions
| ISRCTN | ISRCTN78792722 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN78792722 |
| Integrated Research Application System (IRAS) | 1011519 |
| Protocol serial number | RG_25-038 |
| Sponsor | University of Birmingham |
| Funder | Tommy's |
- Submission date
- 04/11/2025
- Registration date
- 24/02/2026
- Last edited
- 05/10/2026
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Pregnancy and Childbirth
Plain English summary of protocol
Background and study aims
Omega-3 fatty acids play a crucial role in modulating factors linked to the origin and development of recurrent miscarriage, including immune cell dysregulation, oxidative stress, and inflammation. Long-chain polyunsaturated fatty acids (LCPUFAs), specifically docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), play a vital role in gestational health, particularly in influencing gestational length in singleton pregnancies. Studies have shown that adequate intake of these fatty acids during pregnancy is associated with a reduced risk of preterm birth and may promote longer gestation periods.
Miscarriage and preterm birth share several common causes, including inflammation, which can adversely affect pregnancy outcomes. Given these shared causes, interventions designed to prevent preterm birth—such as nutritional supplementation, lifestyle modifications, and pharmacological therapies—could also prove beneficial in reducing the risk of miscarriage.
It remains unknown whether DHA deficiency or insufficiency reduces the risk of miscarriage. At the moment, there are no strategies in the NHS in the UK to increase DHA levels and potentially reduce the risk of miscarriage. The study's definitive primary objective is to test the hypothesis that DHA supplementation at two different doses, used alone, increases the rate of live birth ≥ 34 weeks of gestation by at least 8% in women who have experienced two or more miscarriages. The intermediate primary objective is to test the hypothesis that DHA supplementation at two different doses, used alone, increases the rate of ongoing pregnancy, at 11-14 weeks, by at least 10% in women who have experienced two or more miscarriages.
Who can participate?
Females aged 16 years or over who have experienced two or more previous miscarriages, actively trying to become pregnant, and have confirmation of positive pregnancy test
What does the study involve?
Participants will be randomly assigned to one of three groups:
Control group: no DHA (omega 3)
Low dose group: 750 mg of (omega 3) DHA per day
High dose group: 1125 mg of (omega 3) DHA per day
The low dose will be taken as two capsules daily, and the high dose as three capsules daily, both taken by mouth until 24 weeks of pregnancy.
These doses were chosen based on a thorough review of existing research and the known safety of the supplement. Because there is variation in the evidence about the best amount of DHA to take during pregnancy, the study will test both the low and high dose options.
What are the possible benefits and risks of participating?
Despite the benefits, many pregnant individuals do not consume sufficient levels of DHA and EPA, highlighting the need for increased awareness and potential dietary interventions to optimise pregnancy outcomes. The participants randomised to receive the omega-3 supplements will be provided with omega-3 supplements at no cost and as part of the care pathway.
There are no known risks to taking DHA (omega-3) supplements. However, any queries that arise may be discussed with the participants local care team.
Where is the study run from?
University of Birmingham, UK
When is the study starting and how long is it expected to run for?
August 2026 to May 2030
Who is funding the study?
Tommy's Charity, UK
Who is the main contact?
Mr Lee Priest, Research Fellow/Team Leader, l.priest.1@bham.ac.uk, premis@trials.bham.ac.uk
Contact information
Scientific, Public
Tommy’s National Centre for Miscarriage Research (Birmingham)
Department of Metabolism and Systems Science
School of Medical Sciences
College of Medicine and Health
University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom
| l.priest.1@bham.ac.uk |
Principal investigator
Mindelsohn Way
Edgbaston, Birmingham
B15 2TH
United Kingdom
| r.k.smith@bham.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Open (masking not used) |
| Control | Placebo |
| Assignment | Parallel |
| Purpose | Treatment |
| Scientific title | PREMIS: Preventing miscarriage through platform testing of multiple (novel) interventions. Intervention 1: DHA trial: Docosahexaenoic acid (DHA) (omega-3) to improve live birth rate in women with previous miscarriage |
| Study acronym | PREMIS |
| Study objectives | Definitive primary objective: To test the hypothesis that docosahexaenoic acid (DHA) (omega-3) supplementation increases the rate of live birth ≥ 34 weeks of gestation by at least 8% in women with a history of two or more previous miscarriages. Intermediate primary objective: To test the hypothesis that docosahexaenoic acid (DHA) (omega-3) supplementation increases the rate of ongoing pregnancy at 11-14 weeks by at least 10% in women a history of two or more previous miscarriages. To assess the effect of DHA supplementation on additional clinical and safety outcomes. |
| Ethics approval(s) |
Approved 13/02/2026, West Midlands – Edgbaston Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8155; edgbaston.rec@hra.nhs.uk), ref: 25/WM/0241 |
| Health condition(s) or problem(s) studied | Medical condition: Miscarriage Medical condition in lay language: Miscarriage Therapeutic areas: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
| Intervention | Randomisation will be conducted by a computer algorithm in a 1:1:1 (control:intervention:intervention) ratio to either the control arm, omega-3 intervention low-dose arm (750mg) or the high-dose arm (1125mg). The choice of 750 mg (two capsules) and 1125 mg (three capsules) daily was made after a) careful review of the existing literature and b) the safety profile of the supplement. Due to variation in the evidence base regarding the optimal level of DHA to consume, two intervention arms will be investigated: 1. 750mg docosahexaenoic acid (2 capsules) daily, taken orally until 24 weeks of gestation. 2. 1125mg docosahexaenoic acid (3 capsules) daily, taken orally until 24 weeks of gestation. |
| Intervention type | Supplement |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) |
The following secondary outcome measures will be collected using a questionnaire at one timepoint: |
| Completion date | 31/07/2030 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Mixed |
| Lower age limit | 16 Years |
| Upper age limit | 50 Years |
| Sex | Female |
| Target sample size at registration | 1943 |
| Key inclusion criteria | 1. Written informed consent to receive DHA (omega-3) supplements 2. Patient confirmation of positive pregnancy test 3. Fish consumption - 0, 1 or 2 portions per week (1 portion defined as 140g or 4.9oz when cooked) |
| Key exclusion criteria | 1. Currently taking omega-3 supplementation with DHA concentration >300mg and unwilling to stop 2. Sensitive or allergic to fish or seafood |
| Date of first enrolment | 01/11/2026 |
| Date of final enrolment | 31/01/2030 |
Locations
Countries of recruitment
- United Kingdom
- England
- Northern Ireland
- Scotland
- Wales
Study participating centres
Aberdeen
AB25 2ZN
Scotland
Leicester
LE1 5WW
England
Arrowe Park Road
Wirral
CH49 5PE
England
Edgbaston
Birmingham
B15 2TG
England
Coventry
CV2 2DX
England
Chertsey
KT16 0PZ
England
Burnley
BB10 2PQ
England
Ipswich
IP4 5PD
England
Worthing
BN11 2DH
England
Lewes Road
Haywards Heath
RH16 4EX
England
Brighton
BN2 5BE
England
Chichester
PO19 6SE
England
London
W2 1NY
England
Haywards Heath
RH16 4EX
England
Bristol
BS2 8EG
England
Stockton-on-tees
TS19 8PE
England
Newcastle upon Tyne
NE1 4LP
England
Aylesbury
HP21 8AL
England
Maidstone
ME16 9QQ
England
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan | Requests for the final dataset can be made through the chief investigator, Dr Rima Dhillon-Smith, r.k.smith@bham.ac.uk, in accordance with the data-sharing policies of Birmingham Clinical Trials Unit, Tommy’s National Centre for Miscarriage, University of Birmingham. Only scientifically sound proposals from appropriately qualified research groups will be considered for data sharing. The request will be reviewed by the trial management group, or where appropriate (in absence of the chief investigator) any of the following: the Trial Sponsor, and independent trial steering committee. |
Editorial Notes
05/10/2026: Date of first enrolment was changed from 01/10/2026 to 01/11/2026.
18/08/2026: Date of first enrolment was changed from 01/08/2026 to 01/10/2026.
15/06/2026: Date of first enrolment was changed from 01/06/2026 to 01/08/2026.
14/04/2026: Date of first enrolment was changed from 01/04/2026 to 01/06/2026.
21/02/2026: ISRCTN received notification of combined HRA/MHRA approval for this trial on 21/02/2026.
04/11/2025: Study's existence confirmed by Health Research Authority (HRA) (UK).